Instruction for use: Cassadan 0.25

Dosage form: tablets

Active substance: Alprazolam*

ATX

N05BA12 Alprazolam

Pharmacological group:

Anxiolytic agent (tranquilizer) [Anxiolytics]

The nosological classification (ICD-10)

F29 Inorganic psychosis, unspecified: Childhood psychoses; Psychomotor agitation in psychoses; Hallucinatory-delusional disorders; Hallucinatory-delusional syndrome; Intoxication psychosis; Manic-delusional disorders; Manic chronic psychosis; Manic psychosis; Acute psychosis; paranoid psychosis; Paranoid psychosis; Subacute psychosis; Presenile psychosis; Psychosis; Intoxicating psychosis; Psychosis is paranoid; Psychosis in children; Reactive psychosis; Chronic psychosis; Chronic hallucinatory psychosis; Chronic psychosis; Chronic psychotic disorder; Schizophrenic psychosis

F32 Depressive episode: Adynamic subdepression; Astheno-adynamic subdepressive states; Asthenodepressive disorder; Astheno-depressive disorder; Asthenodepressive state; Astheno-depressive state; Major Depressive Disorder; Vyaloapatichesky depression with retardation; Double depression; Depressive pseudodement; Depressive illness; Depressive mood disorder; Depressive disorder; Depressive mood disorder; Depressive state; Depressive disorders; Depressive syndrome; Depressive syndrome larviated; Depressive syndrome with psychoses; Depressed masks; Depression; Depression Depletion; Depression with the phenomena of inhibition within the framework of cyclothymia; Depression is smiling; Involutional depression; Involutionary melancholy; Involutional depression; Manic-depressive disorder; Masked Depression; Melancholic Attack; Neurotic depression; Neurotic depression; Shallow Depression; Organic depression; Organic depressive syndrome; Simple depression; Simple melancholic syndrome; Psychogenic depression; Reactive depression; Reactive depression with moderate psychopathological symptoms; Reactive depressive states; Reactive depression; Recurrent depression; Seasonal depressive syndrome; Severostatic depression; Senile Depression; Senile Depression; Symptomatic Depression; Somatogenic depression; Cyclotymic depression; Exogenous Depression; Endogenous depression; Endogenous Depressive Conditions; Endogenous Depression; Endogenous depressive syndrome

F40 Phobic anxiety disorders: A state of fear; Fear; Phobia; Phobic disorders; Phobias; Anxiety neurosis; Anxiety of anxiety; Obsessive fears; Acute anxiety disorder; Paroxysmal fear syndrome; Feeling of fear; Night Fears

F41 Other anxiety disorders: Anxiety status; Anxiety; Chronic alarm; Sense of anxiety; Anxious-hypothetical states; Stopping an alarm; Nonpsychotic anxiety disorders

F41.2 Mixed anxiety and depressive disorder: Depression with anxiety-depressive components; Mixed anxiety-depressive conditions; Anxiety Depression; Anxious and depressing mood; Anxiety-depressive state; Anxious-depressive conditions; Anxiety-depressive syndrome; Anxious-Neurotic Conditions

F44 Dissociative [conversion] disorders: Psychogenic psychosis; Conversion disorder; Dissociative phenomena; Pseudodegmentation; Conversion symptoms

F48 Other neurotic disorders: Neurosis; Neurological diseases; Neurotic disorders; Neurotic condition; Psychoneurosis; Anxious-Neurotic Conditions; Chronic neurotic disorders; Emotional reactive disorders

Composition and release form

1 tablet contains alprazolam 0.25 or 0.5 mg, in the package 10, 20 and 50 pcs.

Pharmachologic effect

Mode of action - antidepressive, anxiolytic.

Indications of the drug Cassadan 0,25

States of fear, anxiety; Neurotic or reactive depression; Supportive therapy of endogenous psychoses, mainly anxiety-agitated depression.

Contraindications

Hypersensitivity, male, acute angle-closure glaucoma, acute intoxication of alcohol, painkillers, sleeping pills and psychotropic drugs, pregnancy, lactation, age (under 18 years).

Side effects

Fatigue, dizziness, impaired motor coordination, muscle weakness, headaches, depression, insomnia, nervousness, fearfulness, jitter, anterograde amnesia, autonomic disorders, agitation, irritability, confusion, hallucinations, violations of the right attitude to the environment, articulation disorders, paradoxical reactions, anorexia, nausea, diarrhea, disorders of the liver, jaundice, depression of respiration, a slight decrease in blood pressure, increased salivation, weight change eating, disorders of the menstrual cycle, changes in libido, urinary incontinence, increased intraocular pressure, dermatitis.

Interaction

Potentsiruet action of muscle relaxants, psychotropic drugs; Is incompatible with alcohol. Cimetidine and antibiotics-macrolides increase the concentration in the blood serum. When combined, there was an increase in the levels of imipramine and desipramine in serum by 1/3.

Dosing and Administration

Established individually, taking into account the severity of the symptoms of the disease. The initial daily dose is usually 0.75-1.5 mg. If necessary, the dose can be gradually increased to a maximum of 4 mg / day. When carrying out maintenance treatment, the daily dose varies from 0.5 to 3 mg. The multiplicity of the drug is 2-3 times a day. Elderly patients and immunocompromised patients should be administered at reduced doses: 0.25 mg 2-3 times a day. Continuous use should not exceed 3 months. If it is necessary to cancel the drug, reduce it gradually (especially if used long and at high doses).

Storage conditions of the drug Cassadan 0,25

Normal conditions.

Keep out of the reach of children.

Shelf life of the drug Cassadan 0,25

3 years.

Do not use after the expiry date printed on the package.